L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms

Cancer Science

Volumn 99, Issue 12, 2008, Pages 2380-2386

  Kaira, Kyoichi ^a   Oriuchi, Noboru ^a   Imai, Hisao ^a   Shimizu, Kimihiro ^a   Yanagitani, Noriko ^a   Sunaga, Noriaki ^a   Hisada, Takeshi ^a   Tanaka, Shigebumi ^a   Ishizuka, Tamotsu ^a   Kanai, Yoshikatsu ^b   Endou, Hitoshi ^c   Nakajima, Takashi ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; AMINO ACID TRANSPORTER 1 L TYPE; CD31 ANTIGEN; CD34 ANTIGEN; CD98 ANTIGEN; KI 67 ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER SURGERY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE OVEREXPRESSION; GENITAL TRACT CANCER; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LUNG CANCER; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; SOFT TISSUE SARCOMA; THORACOTOMY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD31; ANTIGENS, CD34; ANTIGENS, CD98; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; SARCOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 57349177871     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00969.x     Document Type: Article

References (29)

1. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 1990; 70: 43-77.
2. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273: 23629-32.
3. Oxender DL, Christensen HN. Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 1962; 197: 765-7.
4. Yanagida O, Kanai Y, Chairoungdua A et al. Human 1-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001; 1514: 291-302.
5. Nakanishi K, Matsuo H, Kanai Y et al. LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch 2006; 448: 142-50.
6. Kobayashi H, Ishii Y, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 2005; 90: 233-8.
7. Kaira K, Oriuchi N, Imai H et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III non-small cell lung cancer. Br J Cancer 2008; 98: 742-8.
8. Kaira K, Oriuchi N, Imai H et al. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract 2008; 204: 553-61.
9. Nakanishi K, Ogata S, Matsuo H et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch 2007; 451: 681-90.
10. Nawashiro H, Otani N, Shinomiya N et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 2006; 119: 484-92.
11. Ohkame H, Masuda H, Ishii Y, Kanai Y. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol 2001; 78: 265-71.
12. Tamai S, Masuda H, Ishii Y, Suzuki S, Kanai Y, Endou H. Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size. Cancer Detect Prev 2001; 25: 439-45.
13. Chairoungdua A, Segawa H, Kim JY et al. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem 1999; 274: 28845-8.
14. Matsuo H, Tsukada S, Nakata T et al. Expression of a system l neutral amino acid transporter at the blood-brain barrier. Neuroreport 2000; 11: 3507-11.
15. Buck AC, Schirrmeister HH, Guhlmann CA et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: Does in.vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001; 42: 721-5.
16. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
17. Oda Y, Yamamoto H, Tamiya S et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis within a group of patients, all of whom developed lung metastasis. Modern Pathol 2006; 19: 738-45.
18. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Seminars Cancer Biol 2006; 15: 254-66.
19. Kanai Y, Endou H. Heterodimeric amino acid transporters: Molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2001; 2: 339-54.
20. Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997; 390: 81-5.
21. Oriuchi N, Higuchi T, Ishikita T et al. Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci 2006; 97: 1291-7.
22. Kaira K, Oriuchi N, Otani Y et al. Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: A clinicopathological study. Clin Cancer Res 2007; 13: 6369-78.
23. Kaira K, Oriuchi N, Otani Y et al. Diagnostic usefulness of fluorine-18-α-methyltyrosine positron emission tomography in combination with 18 F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131: 1019-27.
24. Tomiyoshi K, Amed K, Muhammad S et al. Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: L-F-α-methyl tyrosine using separation and purification system. Nucl Med Commun 1997; 18: 169-75.
25. Inoue T, Koyama K, Oriuchi N et al. Detection of malignant tumors: whole-body PET with fluorine-18-α-methyl tyrosine versus FDG - preliminary study. Radiology 2001; 220: 54-62.
26. Watanabe H, Inoue T, Shinozaki T et al. PET imaging of musculoskeletal tumors with fluorine-18-α-methyltyrosine: Comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000; 27: 1509-17.
27. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
28. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.
29. Donnem T, Al-Saad S, Al-Shibli K et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non-small cell lung cancer. Clin Cancer Res 2007; 13: 6649-57.